NCT00844415View on ClinicalTrials.gov

Safety and Tolerability of Dabigatran Etexilate in Adolescents

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 1, 2009

Primary Completion Date

February 1, 2012

Conditions
Venous Thromboembolism
Interventions
DRUG

dabigatran etexilate

2.14 mg/kg BID to a max 150 mg BID

Trial Locations (2)

Unknown

1160.88.00002 Boehringer Ingelheim Investigational Site, Edmonton

1160.88.00001 Boehringer Ingelheim Investigational Site, Ottawa

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY